IL6 and diabetes mellitus: VEGF-A is activated by advanced glycation end products via ERK1/2, P38, and STAT3 in patients with diabetes and the elderly through upregulation of osteocyte-derived IL-6 and secretion [125], and osteocyte apoptosis [125,126].